Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Label-free cervical cancer detection in tissue samples using Raman spectroscopy combined with machine learning technology.

Analytical methods : advancing methods and applications·2026
Same author

Local Consolidative Radiotherapy Combined With Immunochemotherapy for De Novo Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis.

Head & neck·2026
Same author

Digital technologies in care for older adults living alone: a scoping review.

Innovation in aging·2026
Same author

Clinical Diagnosis and Treatment of Ruptured Renal Artery Aneurysm During Pregnancy: A Case Report and Literature Review.

Clinical case reports·2026
Same author

Mechanistic evaluation of pachymic acid in breast cancer via network pharmacology and in vitro validation.

BMC complementary medicine and therapies·2026
Same author

PSMD4 promotes malignant phenotypes and is associated with angiogenesis-related signaling and immune remodeling in hepatocellular carcinoma.

Discover oncology·2026

Related Experiment Video

Updated: May 21, 2025

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

1.6K

The key role of DLX6 in nasopharyngeal carcinoma: metastasis, angiogenesis and tumor immune mechanism.

Hanxuan Yang1,2, Ximing Zeng3, Xiaochuan Chen1,2

  • 1Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

Frontiers in Immunology
|March 18, 2025
PubMed
Summary
This summary is machine-generated.

DLX6 is a key factor in nasopharyngeal carcinoma (NPC) progression, impacting cell growth, metastasis, and immune response. Targeting DLX6 may improve early detection and treatment outcomes for NPC patients.

Keywords:
NPCangiogenesisdistal-less homeobox 6proliferationtumor immunity

More Related Videos

Zebrafish Model of Neuroblastoma Metastasis
05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

2.7K
CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
12:14

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

2.6K

Related Experiment Videos

Last Updated: May 21, 2025

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

1.6K
Zebrafish Model of Neuroblastoma Metastasis
05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

2.7K
CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
12:14

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

2.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Precise gene expression management is crucial for cellular function.
  • Early-stage nasopharyngeal carcinoma (NPC) often leads to delayed diagnosis and poor prognosis.
  • Investigating DLX6 in NPC pathogenesis can improve early screening and treatment strategies.

Purpose of the Study:

  • To investigate the role of DLX6 in nasopharyngeal carcinoma (NPC) pathogenesis.
  • To evaluate DLX6 as a potential biomarker for NPC early screening and prognosis.
  • To explore DLX6 as a therapeutic target for NPC.

Main Methods:

  • Utilized immunohistochemistry and RNA sequencing to analyze DLX6 expression in NPC samples.
  • Performed bioinformatics analysis on clinical and public sequencing data.
  • Assessed the impact of DLX6 knockdown on NPC cell proliferation, invasion, and migration using functional assays.
  • Examined epithelial-mesenchymal transition (EMT) markers and PI3K-AKT pathway proteins via western blot.

Main Results:

  • DLX6 expression correlates with NPC prognosis and is altered in tumor tissues and cells.
  • DLX6 knockdown significantly impaired NPC cell proliferation, invasion, and migration.
  • Bioinformatics analysis linked DLX6 to cell cycle, DNA replication, and cancer progression pathways.
  • DLX6 influences the NPC immune landscape, affecting immune cell infiltration and correlating with immunotherapy response.

Conclusions:

  • DLX6 serves as a novel prognostic biomarker for NPC.
  • DLX6 plays a critical role in NPC metastasis, angiogenesis, and tumor immunity.
  • DLX6 represents a potential therapeutic target for nasopharyngeal carcinoma.